


addresses the vast liposuction and obesity markets with proprietary medical devices and technologies that are F.D.A. approved, fully commercially saleable and protected by over 10 pending U.S. and International Patent Applications and 8 registered trademarks. Liposuction is the most commonly performed elective surgical procedure in the world and the most frequently carried out procedure for obesity. **BST's** proprietary technology has dramatic advantages for both patient and doctor that make liposuction less painful and less physically taxing, with better results and shorter convalescence. The highly qualified and experienced physician founder and management team are well equipped to capitalize on these opportunities and build the company toward a rapid exit.



The worldwide liposuction market itself is vast, and the potential scope of application of the large volume liposuction capability of our twin cannulas technology as an alternative therapy for obesity and associated type II diabetes is also enormous. In 2010 ASPS reported 289,016 liposurgeries, and elective plastic surgery in the U.S. is increased by 63% from 1997 to 2010. The potential market is estimated at \$500 million in device sales, and our clinical component taps a \$854

million yearly U.S. market in surgical fees for per-procedural consumables and brand-based patient referrals. Europe, South America and Asia each equal or surpass the U.S. market in potential size.

BST's gentler-by-design tissue aspiration technology has a number of substantial advantages for both patient and doctor. In our second generation *Airbrush® II* twin-cannula system, only the inner cannula, a tube within a tube, moves, eliminating the to-and-fro battering ram trauma of a single unsheathed cannula being shoved many thousands of times into a patient during a single surgery. Our design helps reduce patient pain, swelling, bruising, unevenness and waviness, blood loss, and the necessity for repeated procedures and shortens convalescence. For the surgeon, by increasing control and eliminating the surgical drudgery, labor and fatigue of manually stroking a single cannula inside the patient, our second generation *Airbrush Liposculpture® System unleashes the artist in the surgeon®*. By reducing anaesthesia time and the necessity of corrective procedures, generally carried out at the surgeon's expense, our system saves the doctor money and pays for itself.



Our tissue removal platform has already been approved by the F.D.A. under a 510(k). Two non-exclusive licenses of the first generation patented technology have successfully tested the market and brought in approximately \$320,000 in royalties. Under one license, **NuMed** and **UAM** manufactured a reusable electric, single cannula device. Under a second, **Byron Medical** and **Mentor**, recently acquired by the **Ethicon Division of J&J**, manufacture a disposable, air-driven,



single cannula device. BioSculpture has opened the Asian market with a pending \$1.65 million order from a major Asian distributor for second generation *Airbrush® II* units. Already compliant with **ISO 9001/13485** controls in place, we are readied for inspection to obtain **certification** for our **CE** to facilitate further sales to Korea, China, Japan, Europe, and South America.

BST's innovative aspiration and collection technology employs reciprocating twin cannulas under **Intellimotion®** control which supports integrated RF-electrocautery and irrigation options and patent pending in-line fat collection, processing and autograft technology, confer numerous advantages to surgeons

in applications and procedures addressing obesity, metabolic syndromes, type II diabetes, and fat autografting. Two of these include large volume liposuction and adaptations for laparoscopic removal of the metabolically more harmful visceral fat as potential alternatives to obesity treatments with gastric banding and intestinal bypass. A U.S. Patent protecting this method and a device designed for it was just allowed.

Patent protection being pursued for our innovative and proprietary technology is broad in scope, and includes numerous apparatus and method claims to invention in fields including, but not limited to: tissue aspiration instruments employing electric and pneumatic powered hand-pieces, twin-cannula assemblies and bi-polar RF-electrocautery and irrigation; adipose fat tissue collection, processing and banking; autografting using stem-cell enriched adipose tissue; endoscopically-guided tissue aspiration instrumentation, and procedures for treating type II diabetes and metabolic syndrome; et al. Eight U.S. trademarks and strong branding offer a technology and treatment double play as **Airbrush® Liposculpture Centers** specializing in liposuction surgery using proprietary method and devices may license the **Airbrush®** brand and pay **BST** royalties for patient referral generated through national advertising.




Over \$1.3 million has been expended for R&D to acquire significant technologic “know how” for present and future products in our pipeline. Ancillary liposuction surgical devices and consumables, including specialized curved cannulas, bipolar cautery, tumescent cannulas, scroll pump aspirators and pulsed infusers, are in the pipeline. Our patented multicore quick connect coupler also has other medical



device as well as aviation, marine and military applications. **Airbrush® Liposculptor III** will target small and medium volume liposuction with attractive pricing and profit margin.

The Mensan inventor of the technology and founder of the company, **R.L. Cucin, CEO** has a Cornell BA and MD, a Fordham JD, and a Columbia MBA. A heavily published board-certified Cornell-trained plastic surgeon, he funded the Rocin Foundation for Plastic Surgical Research to support his continuing academic research. Dr. Cucin set up the American Institute of Plastic Surgery, an accredited ambulatory plastic surgery facility and hosted *Keeping Face and Figure* a syndicated weekly medical information TV talk show that aired for six years. He employed his combined degrees and experience in heading a Biotechnology Analysis and Advisory Service. Twenty years ago Dr. Cucin set up Rocin Laboratories, Inc. as a Research and Development company to perfect therapeutic dermatologicals and biomedical devices. Rocin now has an extensive international patent portfolio, and Bio Sculpture Technology, Inc. was created to fast track commercialization of a closely related selection of those patents.



Deborah Salerno, CFO, has held series 4, 7, 24, and 63 securities licenses. At Bodkin Securities, she syndicated 15 new issue and secondary offerings and arranged the firm’s participation in more than 50 offerings. At Wilshire Securities she became the principal of a dozen blind pool offerings. She has been active in PIPE’s and provides expertise in the alternative Public Offerings market as well as traditional banking. **Simon Taylor, Corporate Counsel** is a Columbia University and Harvard Law School graduate with broad experience with biotechnology and medical devices, technology and IP start-ups and ramp-ups, venture financing, and close ties to the financial community. **Consultant Engineer, Dr. Peter Ciriscioli** received his B.S. and M.S. in Materials Science and Engineering from the University of California and a PhD in Mechanical Engineering from Stanford University. His experience includes heading development of new products at GE Medical Systems, developing Innovation Strategy and composite materials for GE. Industrial Systems. His subsequent work with Applied Research Associates and BAE Systems has included MEMS, composite materials and hybrid electric drives.